Medscape: AFIRE encourages less antiplatelet use with novel oral anticoagulant for atrial fibrillation treatment
UC cardiologist weighs in on trial looking at therapies for heart patients
Medscape turned to the expertise of Richard Becker, MD, Director, UC Heart, Lung and Vascular Institute, when reporting the results of a randomized trial comparing an oral anticoagulation with an antiplatelet agent versus an oral anticoagulation alone in patients with both atrial fibrillation and stable coronary artery disease. Becker, also director of the UC Division of Cardiovascular Health and Disease in the College of Medicine and a UC Health cardiologist, authored a New England Journal of Medicine editorial on the results of the AFIRE trial.
Richard Becker, MD
Related Stories
New UC Center for Alzheimer's and Neurodegenerative Diseases Research to advance dementia research, treatment and education
July 14, 2026
The University of Cincinnati and UC Health are launching the Center for Alzheimer's and Neurodegenerative Diseases Research (CANDR) to advance dementia research, clinical care and brain health education.
UC students organize free health clinic in community
July 13, 2026
The University of Cincinnati student chapter of Remote Area Medical held its annual free health clinic July 11-12 at St. Xavier High School. Medical, dental and vision care was offered to adults and children, with no income requirements or insurance needed.
Hoxworth Blood Center CEO advocates on Capitol Hill during National Blood Advocacy Week
July 9, 2026
Hoxworth Blood Center, University of Cincinnati, has announced that David Oh, MD, director and chief executive officer, joined blood center leaders, patient advocates and partner organizations in Washington, D.C., in June as part of Blood Advocacy Week, a national initiative led by America’s Blood Centers to strengthen the nation’s blood supply.